G
G. M. Besser
Researcher at St Bartholomew's Hospital
Publications - 286
Citations - 15897
G. M. Besser is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Prolactin & Acromegaly. The author has an hindex of 71, co-authored 286 publications receiving 15583 citations. Previous affiliations of G. M. Besser include University of Turin & Kwong Wah Hospital.
Papers
More filters
Journal ArticleDOI
Neuropeptide-Y stimulates CRF-41 release from rat hypothalami in vitro.
TL;DR: Evidence is provided for a direct stimulatory effect of NPY on CRF-41 secretion from the rat hypothalamus in vitro, independent of catecholaminergic interactions, suggesting that it is mediated either directly on CRf-41 neurons or through non-catechlaminergic neuronal systems.
Journal ArticleDOI
An assessment of glucose intolerance in acromegaly and its response to medical treatment.
TL;DR: The prevalence of abnormal carbohydrate tolerance has been assessed in sixty‐nine acromegalic patients using six different criteria for the definition of diabetes mellitus and the effect of 3 months therapy with bromocriptine on oral glucose tolerance has be assessed.
Journal ArticleDOI
A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis
Peter J Trainer,M. Faria,John Newell-Price,P Browne,P Kopelman,D. H. Coy,G. M. Besser,Ashley B. Grossman +7 more
TL;DR: Although ovine sequence CRH causes more prolonged and greater ACTH, and possibly cortisol, secretion compared to human CRH, the discriminatory value of the CRH test, in terms of either the diagnosis or differential diagnosis of Cushing's syndrome, is comparable for the two peptide sequences.
Journal ArticleDOI
Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormones.
G. M. Besser,C. H. Mortimer,A. S. McNEILLY,Michael O. Thorner,G. A. Batistoni,Stephen Robert Bloom,K. W. Kastrup,K. F. Hanssen,Randolph W. Hall,David H. Coy,Abba J. Kastin,Andrew V. Schally +11 more
TL;DR: Longer-acting analogues of GH-RIH will be needed before long-term therapy of acromegaly or diabetes mellitus becomes possible, but such preparations should be available soon for clinical trial.
Journal ArticleDOI
Corticotropin-releasing factor immunoreactivity in human gastrointestinal tract
TL;DR: An antiserum to the 41-aminoacid residue ovine corticotropin-releasing factor (CRF-41) and an immunohistochemical technique were used to demonstrate the presence of CRF- 41 immunoreactivity in the human gastrointestinal tract as well as in the hypothalamus.